4009. The Future of HTN Care is Now: The Symplicity™ Blood Pressure Procedure

Industry-Expert Theater 2, #20077
Sponsored by Medtronic

Join us for an insightful session on renal denervation, a groundbreaking complementary option for managing hypertension. Hear from leading experts as they discuss the latest guidelines, clinical evidence, and patient selection strategies. Engage in interactive discussions and real-world case studies that highlight best practices and shared decision-making. Don't miss this opportunity to enhance your knowledge and improve patient care! Learn more and be part of the future of hypertension management!

Speakers
Tiffany Randolph, MD (Moderator)
Cone Health
Greensboro, NC

Michael Bloch, MD
Renown Health
Reno, NV

Eric Secemsky, MD, MSc
Beth Israel Deaconess
Boston, MA

Debbie Cohen, MD
University of Pennsylvania
Philadelphia, PA

4017. Introduction to AMVUTTRA® (vutrisiran)

Industry-Expert Theater 3, #24076
Sponsored by Alnylam Pharmaceuticals

4002. Finding Lp(a): "Little" Things, Big Consequences

Industry-Expert Theater 1, #16077
Sponsored by Novartis

A disease state (non-CME), interactive Expert Panel presentation and discussion on lipoprotein(a).

Speakers
James Donnelly, PhD, MBA
Senior Advisor Clinical Laboratories Northwell Health

Nathan D. Wong, PhD
Professor, Medicine
University of California, Irvine
School of Medicine
Director, UCI Heart Disease Prevention Program (Preventive Cardiology)

4010. Cases, Clues and Collaboration: A Team Approach to Identifying Obstructive Hypertrophic Cardiomyopathy (oHCM)

Industry-Expert Theater 2, #20077
Sponsored by Cytokinetics

During this collaborative, interactive session, our speaker faculty will discuss the spectrum of symptoms and subtle indicators of oHCM that are often overlooked in clinical practice. This multidisciplinary panel will further explore the impact of early recognition and management of oHCM from the perspectives of both practitioners and patients.

4018. Managing Coagulopathic Bleeding in Cardiac Surgery With Coagulation Factor Concentrates

Industry-Expert Theater 3, #24067
Sponsored by CSL Behring

In this CSL Behring-sponsored Industry Expert Theater session, Dr Henderson will review current guidelines and clinical practices for the management of coagulopathic bleeding in cardiac surgery. Dr Henderson will go on to explore the historical safety data for four-factor prothrombin complex concentrate and fibrinogen concentrate before discussing the most recent evidence on the use of coagulation factor concentrates, including prothrombin complex concentrate and fibrinogen concentrate, in cardiac surgery.

Speaker
Reney A. Henderson Jr, MD
Associate Professor, Associate Fellowship Director, Cardiothoracic Anesthesiology
Department of Anesthesiology, Division of Cardiothoracic Anesthesia
University of Maryland School of Medicine
Baltimore, MD, USA

4003.Learn How to Identify and Help Your Patients With ASCVD Lower Their LDL-C

Industry-Expert Theater 1, #16077
Sponsored by Amgen

Join our experts for an insightful presentation on a treatment option and recommendations from the 2022 ACC Expert Consensus Decision Pathway. Discover the latest on achieving lower LDL-C levels and the lower threshold for managing very high-risk ASCVD patients.

Speaker
Peter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACC
Director of Preventive Cardiology
CGH Medical Center
Professor of Clinical Family and Community Medicine
University of Illinois School of Medicine
Adjunct Professor of Medicine
Division of Cardiology
Johns Hopkins University School of Medicine

4011. Title to be announced

Industry-Expert Theater 2, #20077
Sponsored by AstraZeneca

4019. Spotlight on a Treatment Option For Pulmonary Arterial Hypertension (PAH)

Industry-Expert Theater 3, #24067
Sponsored by Merck & Co

Learning Objectives:

• Understand PAH as a progressive, life-threatening disease with a poor prognosis.
• Review a treatment option that targets a key pathway implicated in PAH.
• Review clinical data from a phase 3 trial supporting the approval of a treatment option for appropriate adults with PAH.

Speaker
Ioana Preston, MD
Director of the Pulmonary Hypertension Center
Lahey Hospital and Medical Center

4004. Real-World Data Meets Clinical Practice For Patients With ATTR-CM

Industry-Expert Theater 1, #16077
Sponsored by Pfizer

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized, and underdiagnosed cause of heart failure. Through a patient case study and expert perspectives, this program will explore the patient journey for ATTR-CM, including sharing long-term extension data and recently published findings from a real-world study for an oral treatment option for patients with this progressive disease.

4012. Backed by LEQVIO® (inclisiran) Data: Why Adherence Matters

Industry-Expert Theater 2, #20077
Sponsored by Novartis Pharmaceuticals Corporation

Interested in hearing about the real-world adherence data for LEQVIO? This insightful presentation will explore the importance of adherence and how LEQVIO can be used in appropriate patients.

Speakers
David Kwon, MD, PhD, MBA
Senior Medical Director, US Medical Affairs
Novartis Pharmaceuticals Corporation

KaJuan Billings
Executive Director, Access & Reimbursement
Novartis Pharmaceuticals Corporation

4020. The Impact of Cardiac Myosin Inhibition on Cardiac Structure and Function

Industry-Expert Theater 3, #24067
Sponsored by Bristol Myers Squibb

Join this session to review the natural history and prognostic markers of HCM and discuss the impact of cardiac myosin inhibition on cardiac structure and function outcomes in adult patients with symptomatic NYHA Class II-III obstructive HCM from pivotal trial and long-term extension data.

Speaker
Anjali Tiku Owens, MD

4005. From Evidence Generation to Implementation: Tackling Unmet Need in ASCVD

Industry-Expert Theater 1, #16077
Sponsored by Amgen

Dr. Bhatt and Dr. Marvel highlight how real-world evidence reveals critical gaps in LDL-C management. Join them as they unpack the power of implementation science and the transformative work of the LATTICE Consortium projects.  LATTICE™ is Leading Awareness to Action Through Implementation of Cardiometabolic Efforts.

Speakers 
Francoise A. Marvel, MD

Ankeet S. Bhatt, MD, MBA, ScM

4013. Systemic Inflammation in CVD: Perspectives in Heart Failure

Industry-Expert Theater 2, #20077
Sponsored by Novo Nordisk

During this symposium, our expert faculty Sanjiv Shah, Brittany Weber and Marat Fudim will discuss the role of phenotyping in HFpEF and its applicability to clinical practice before discussing the role of systemic inflammation in HFmrEF/HFpEF. An overview of the relevant inflammatory pathways will be provided and the clinical utility of hsCRP as a biomarker for systemic inflammation will be discussed. Finally, the current evidence supporting the role of systemic inflammation and anti-inflammatory therapies in HFmrEF/HFpEF will be explored. Attendees will have the opportunity to ask questions to the faculty in live Q&A sessions throughout the symposium.

Speakers
Sanjiv Shah, MD
Professor
Northwestern University
Illinois, Chicago

Brittany Weber, MD, PhD
Brigham and Women's Hospital
Boston, Massachusetts

Marat Fudim, MD, MHS
Associate Professor
Duke University
Durham, North Carolina

4021. Title to be announced

Industry-Expert Theater 3, #24067
Sponsored by Kiniksa Pharmaceuticals

4006. Title to be announced

Industry-Expert Theater 1, #16077
Sponsored by Boston Scientific

4014. Shifting the Paradigm: Lipoprotein(a) in Cardiovascular Disease

Industry-Expert Theater 2, #20077
Sponsored by Amgen

Join renowned cardiology experts Dr. Martha Gulati and Dr. Alan Brown as they explore the fundamentals of Lipoprotein(a) and its impact on atherosclerotic cardiovascular disease (ASCVD) risk. This session will provide a detailed foundation for understanding Lipoprotein(a) and its clinical relevance in ASCVD management.

Speakers
Martha Gulati, MD, MS, FACC, FAHA
Professor of Cardiology
Cedars Sinai Medical Center
Los Angeles, CA

Alan Brown, MD, FACC, FAHA, FNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, Illinois

4022. Title to be announced

Industry-Expert Theater 3, #24067
Sponsored by Eli Lilly & Company

007. Evolving Perspectives on Hypertension Secondary to Hypercortisolism: A Panel Discussion

Industry-Expert Theater 1, #16077
Sponsored by Corcept Therapeutics

Case-based panel discussion on evolving perspectives in endogenous hypercortisolism.

Speakers
David R. Brown, MD, PhD
Private Practice Endocrinology, Diabetes, and Metabolism
Rockville, MD

Jorge Plutzky, MD, FACC, FNLA
Director, Preventive Cardiology
Cardiovascular Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

Pam R. Taub, MD, FACC, FASPC
Director of Preventive Cardiology
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
La Jolla, California

4015. Overcoming the Hurdles: Address CV Risk and Weight in Appropriate Patients

Industry-Expert Theater 2, #20077
Sponsored by Novo Nordisk

Recognize obesity as a chronic, progressive disease and explore the relationship between obesity and cardiovascular disease (CVD). Discuss the need to address cardiovascular (CV) risk and weight in adults with CVD and obesity or overweight. Analyze the efficacy and safety data from a cardiovascular outcomes trial as well as from relevant chronic weight management trials.

Speaker
Sanjay Rajagopalan MD, MBA, FACC, FAHA
Chief, Cardiovascular Medicine and Chief Academic and Scientific Officer
University Hospitals Harrington Heart & Vascular Institute
Herman K. Hellerstein MD, Professor of Cardiovascular Medicine
Professor, Department of Internal Medicine and Biomedical Engineering
Case Western Reserve University
Cleveland, Ohio

4023. Insights to Impact in ATTR-CM: Bringing New Data and Treatments Into Routine Care

Industry-Expert Theater 3, #24067
Sponsored by MedscapeLIVE

4008. AAV Gene Therapy in Heart Failure: Discussion About GenePHIT, a Phase II Trial of AB-1002 For the Treatment of Heart Failure

Industry-Expert Theater 1, #16077
Sponsored by AskBio

Heart Failure (HF) is a multi-faceted and life-threatening disease characterized by significant morbidity and mortality. Despite recent advancements in treatment approaches for HF, a high unmet therapeutic need exists in patients living with this disease. Gene therapy is being investigated as an approach to treat HF based on its potential to improve heart function. This educational symposium brings together an expert faculty to discuss the past, present, and future of cardiac gene therapy and highlight GenePHIT, a Phase 2 trial of AB-1002 (designed to block the action of protein phosphatase 1) for the treatment of HF using AAV-based gene therapy.
Foot note: AB-1002 is investigational gene therapy and not approved by the FDA or EMEA.

Speakers
Roger Hajjar, MD
Massachusetts General Brigham
Cambridge, MA, USA

Timothy Henry, MD
Christ Hospital
Cincinnati, OH, USA

JoAnn Lindenfeld, MD
Vanderbilt University Medical Center
Nashville, TN, USA

Javed Butler, MD
Baylor Scott & White Research Institute
Dallas, TX, USA

4016. A Major Milestone in the Treatment of Familial Chylomicronemia Syndrome (FCS)

Industry-Expert Theater 2, #20077
Sponsored by Ionis Pharmaceuticals

Join IONIS to learn about TRYNGOLZATM – the first and only FDA-approved therapy for adults with familial chylomicronemia syndrome (FCS), and what it may mean for your patients! Please see Important Safety Information and full Prescribing Information for TRYNGOLZA at TRYNGOLZAHCP.com.

Speaker
Alan Brown
MD, MHA, FACC, FAHA, MNLA
Director of the Lipid Clinic
Advocate Health and Hospitals Corporation
Lutheran General Hospital
Chicago, IL

4024. Exploring EVKEEZA® (evinacumab-dgnb)

Industry-Expert Theater 3, #24067
Sponsored by Regeneron

• Early detection and intervention in HoFH
• Mechanism of action for EVKEEZA
• Clinical efficacy and safety of EVKEEZA
• Long-term (48 weeks*) efficacy and safety of EVKEEZA
• Dosing and administration for EVKEEZA
• myRARE®: Patient support for EVKEEZA

*48-week study (24-week double-blind treatment period followed by 24-week open-label treatment period)

Speaker
Alan S. Brown, MD, MHA, FACC, FAHA, FASPC, MNLA